期刊
MOLECULAR PSYCHIATRY
卷 16, 期 1, 页码 26-36出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2010.51
关键词
hematopoietic growth factor; neuroregeneration; neuroprotection; voxel-based morphometry; brain atrophy; cognition; schizophrenia
资金
- Max Planck Society
- DFG Research Center for Molecular Physiology of the Brain (CMPB)
Neurodevelopmental abnormalities together with neurodegenerative processes contribute to schizophrenia, an etiologically heterogeneous, complex disease phenotype that has been difficult to model in animals. The neurodegenerative component of schizophrenia is best documented by magnetic resonance imaging (MRI), demonstrating progressive cortical gray matter loss over time. No treatment exists to counteract this slowly proceeding atrophy. The hematopoietic growth factor erythropoietin (EPO) is neuroprotective in animals. Here, we show by voxel-based morphometry in 32 human subjects in a placebo-controlled study that weekly high-dose EPO for as little as 3 months halts the progressive atrophy in brain areas typically affected in schizophrenia, including hippocampus, amygdala, nucleus accumbens, and several neocortical areas. Specifically, gray matter protection is highly associated with improvement in attention and memory functions. These findings suggest that a neuroprotective strategy is effective against common pathophysiological features of schizophrenic patients, and strongly encourage follow-up studies to optimize EPO treatment dose and duration. Molecular Psychiatry (2011) 16, 26-36; doi:10.1038/mp.2010.51; published online 18 May 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据